"Evaluating The Applicability of LASMAR Scoring in Predicting Surgical Outcomes Of Hysteroscopic Myomectomy"

Evaluating The Applicability of LASMAR Scoring in Predicting Surgical Outcomes Of Hysteroscopic Myomectomy"

This study aims to evaluate the applicability of the LASMAR scoring system, derived from hysteroscopy, in predicting surgical outcomes in patients undergoing hysteroscopic myomectomy for submucous fibroids.

Study Overview

• Status: Not yet recruiting
• Conditions: LAZMAR Scoring , Hysteroscopic Myomectomy
• Intervention / Treatment: Procedure: Hysteroscopic Myomectomy

Detailed Description

This study aims to evaluate the applicability of LASMAR scoring in predicting surgical outcomes for cases of hysteroscopic myomectomy. By applying the LASMAR scoring system to patient , the study seeks to determine if the scoring can accurately predict operative time, completeness of resection, and complication rates.

• Study Type: Observational
• Enrollment (Estimated): 88

Contacts and Locations

• Study Contact: Name: Yomna Ayman Salah, Master degree; Phone Number: 01060666006; Email: yomnasalah@med.asu.edu.eg
• Study Contact Backup: Name: Ahmed Mohammed Selim, MD; Phone Number: 011 15330063

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Women undergoing hysteroscopic myomectomy for symptomatic uterine fibroids.

Description

Inclusion Criteria:

• Women aged 18-45 years
• Type 0,1,2 Fibroids according to Figo classification.
• Symptomatic submucous fibroids: Symptoms include abnormal uterine bleeding, pelvic pain or pressure symptoms, infertility or recurrent pregnancy loss.
• Fibroids size ≤ 5 cm in diameter
• Confirmed diagnosis of leiomyoma by ultrasound .
• Hemodynamically Stable Patients: Patients with no significant anemia.

Exclusion Criteria:

• Contraindications to hysteroscopy (e.g., Pregnancy, pyometra, active infection)
• Individuals with significant comorbidities (e.g., severe cardiovascular or respiratory diseases, bleeding diathesis).
• Cases requiring concurrent procedures (e.g., Laparoscopic surgeries).
• Fibroid Size>5 cm.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between preoperative parameters assessed using the Lasmar score and operative parameters, including operative time, number of sessions needed for complete resection, fluid deficit and intraoperative complications.	Correlation between preoperative parameters assessed using the Lasmar score and operative parameters, including operative time, number of sessions needed for complete resection, fluid deficit and intraoperative complications	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Postoperative Complications: Including infection, adhesions, volume overload.	Postoperative Complications: Including infection, adhesions, volume overload.	2 years
Need for Further Interventions: Incidence of additional treatments like hormonal therapy	Need for Further Interventions: Incidence of additional treatments like hormonal therapy	2 years

Collaborators and Investigators

• Sponsor: Ain Shams University

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): July 1, 2028

Study Registration Dates

• First Submitted: May 5, 2026
• First Submitted That Met QC Criteria: May 5, 2026
• First Posted (Actual): May 11, 2026

Study Record Updates

• Last Update Posted (Actual): May 11, 2026
• Last Update Submitted That Met QC Criteria: May 5, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: OBGYN-HYST-2026-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No